Collectively, these data suggest that TRIM6 functions as a critical regulator of ICB resistance in gastric cancer, and genetic ablation of TRIM6 substantially sensitizes gastric tumors to anti-PD-L1 therapy. Here, CD274 is linked to gastric neoplasm.